Table 2.
Published data on the use of bromfenac 0.09% for the treatment of CME
| Study | Study design | Treatment groups | Findings |
|---|---|---|---|
| Rho et al75 | Prospective | Patients exhibiting CME within 1 year after uncomplicated cataract surgery, treated with one of the following drugs for 3 months: – bromfenac 0.09% BID (n=62) – diclofenac 0.1% QID (n=52) – ketorolac 0.5% QID (n=52) |
All treatments resulted in an improvement in VA with a significant difference in favor of bromfenac compared to ketorolac (P=0.036) |
| Saviano et al76 | Case report | 69-year-old white woman with CME 16 days after uncomplicated phacoemulsification cataract surgery. Standard postop regimen (tobramycin/dexamethasone/diclofenac) was discontinued on day 16, and bromfenac 0.9 mg/mL BID was initiated | Five days after bromfenac was initiated, the OCT showed a reduction in central foveal retinal thickness (from 857 to 205 μm) and optically empty intraretinal spaces. Treatment was continued for another 14 days. At follow-up ~1 month after bromfenac was initiated, CME was resolved; retinal thickness was 203 μm and the corrected distance VA was 0.00 logMAR |
| Warren et al77 | Prospective, randomized, investigator masked | 39 patients with chronic pseudophakic CME randomized to treatment with one of the following drugs for 16 weeks: – diclofenac 0.1% TID (n=7) – ketorolac 0.4% TID (n=8) – nepafenac 0.1% TID (n=8) – bromfenac 0.09% BID (n=8) – placebo BID (n=8) All patients also received intravitreal triamcinolone (at study entry) and bevacizumab injections (at study entry and at 1 month) |
Compared with placebo, bromfenac and nepafenac produced significantly greater reductions in retinal thickness at 12 and 16 weeks. VA improvement at week 16 was significant only in the nepafenac-treated group |
| Kadrmas78 | Retrospective | 11 cases of CME unresponsive to ketorolac 0.4% QID treatment following cataract surgery subsequently switched to treatment with bromfenac 0.09% BID; length of bromfenac treatment averaged 20.1 weeks (range 10–40 weeks) compared to previous treatment with ketorolac of 23 weeks (range 9–50 weeks) | All 11 eyes showed complete resolution of CME after treatment with bromfenac as well as an average visual improvement of 12.7 Snellen letters (SEM 3.8 letters). The mean (SEM) decrease in central macular thickness and central macular volume was 58.3 μm (17.6 μm) and 0.18 mm3 (0.05 mm3), respectively |
Abbreviations: CME, cystoid macular edema; OCT, optical coherence tomography; SEM, standard error of the mean; postop, postoperative; VA, visual acuity.